Physician profile
Ian V Mackey
NPI 1720109424
$134,991.43
in general payments reported to CMS, 2019-2025
39 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10K · 2022: $13K · 2023: $20K · 2024: $31K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Honoraria: $35K · Food and Beverage: $17K · Consulting Fee: $12K · Travel and Lodging: $8,366 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,600 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,000.00 |
| Honoraria | $35,301.00 |
| Food and Beverage | $17,170.91 |
| Consulting Fee | $12,054.00 |
| Travel and Lodging | $8,366.17 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,600.00 |
| Education | $147.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59,843.67 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $51,865.15 | 2022-2025 | Auvelity, Sunosi |
| Janssen Scientific Affairs, LLC | $3,790.00 | 2023-2025 | Spravato |
| Abbvie INC. | $2,979.61 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,396.65 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,962.57 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $1,350.66 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $1,247.27 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $1,239.98 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $1,091.02 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $967.25 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $694.46 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Bausch Health US, LLC | $651.08 | 2021-2025 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $592.14 | 2024-2025 | Cobenfy |
| Corium, LLC | $477.83 | 2022-2025 | Azstarys |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $333.45 | 2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $328.33 | 2022-2025 | Xelstrym, Secuado |
| Neos Therapeutics, Lp | $323.27 | 2022-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $317.19 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $305.93 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $298.43 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $273.14 | 2021-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $267.97 | 2022-2025 | Dyanavel Xr |
| Livanova USA, INC. | $166.71 | 2021-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Eisai INC. | $155.37 | 2021 | |
| Biogen, INC. | $136.01 | 2021-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $123.08 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $109.82 | 2025 | Jornay Pm |
| Azurity Pharmaceuticals, INC. | $104.68 | 2023-2024 | Horizant, Horizant |
| Harmony Biosciences LLC | $98.95 | 2022-2025 | |
| Indivior INC. | $92.03 | 2022-2024 | Perseris |
| Novo Nordisk INC | $87.14 | 2024-2025 | Wegovy |
| Uswm, LLC | $80.71 | 2022-2023 | Lucemyra, Zimhi |
| Bioxcel Therapeutics, INC. | $71.54 | 2023-2024 | Igalmi |
| Tempus Ai, INC | $52.63 | 2024 | |
| Alfasigma USA, INC. | $43.41 | 2021 | |
| Braeburn INC. | $31.48 | 2025 | Brixadi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.38 | 2025 | Rejoyn |
| Acadia Pharmaceuticals INC | $16.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.